Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Holding CPRX?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.34Last Year’s EPS
$0.31Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -6.34%
|Next Earnings Date:Mar 12, 2025
Earnings Call Sentiment|Positive
The earnings call presented strong financial performance and positive growth, particularly with FIRDAPSE and AGAMREE. Despite a decline in FYCOMPA revenues and increased SG&A expenses, the company's overall financial position and strategic initiatives, including global expansion efforts, indicate a positive outlook.Company Guidance
In the Catalyst Pharmaceuticals Q3 2024 earnings call, the company provided updated financial guidance driven by strong performances of key products. Total revenues for the quarter were reported at $128.7 million, reflecting a 25.3% year-over-year increase, with net product revenues of $126.4 million, up by 23.2%. The robust performance was largely attributed to FIRDAPSE, which generated $79.3 million in net sales, a 19.7% increase, and AGAMREE, with net sales of $15 million. Consequently, Catalyst revised its full-year 2024 revenue guidance to between $475 million and $485 million. FIRDAPSE's annual guidance was adjusted to a range of $300 million to $310 million, while AGAMREE's projections were raised to between $40 million and $45 million. FYCOMPA also contributed $32.1 million in Q3 net revenues, despite a 12% decrease due to adjustments in gross-to-net deductions. The company emphasized its commitment to strategic initiatives, including global expansion and clinical studies, to sustain long-term growth.Revenue Growth and Updated Guidance
Total revenues for Q3 2024 were $128.7 million, a 25.3% increase year-over-year. Full-year 2024 revenue guidance was updated to between $475 million and $485 million.
FIRDAPSE Performance
Q3 net sales of FIRDAPSE were $79.3 million, a 19.7% increase over the same quarter last year. Full-year revenue guidance for FIRDAPSE updated to between $300 million and $310 million.
AGAMREE Market Success
AGAMREE's Q3 net sales reached $15 million, with full-year revenue guidance increased to between $40 million and $45 million.
Global Expansion Milestones
Regulatory approval for FIRDAPSE in Japan, with a milestone payment of $2.1 million. Efforts underway for AGAMREE's regulatory approval in Canada.
Strong Financial Position
End of Q3 2024 cash and cash equivalents were $442.3 million, reflecting a significant increase from $137.6 million at the end of 2023.
---
CPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $22.71 | $23.25 | +2.38% |
| Aug 07, 2024 | $16.23 | $18.30 | +12.75% |
| May 08, 2024 | $14.72 | $15.65 | +6.32% |
| Feb 28, 2024 | $14.56 | $16.03 | +10.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Catalyst Pharma (CPRX) report earnings?
Catalyst Pharma (CPRX) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Catalyst Pharma (CPRX) earnings time?
Catalyst Pharma (CPRX) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CPRX EPS forecast?
CPRX EPS forecast for the fiscal quarter 2024 (Q4) is $0.34.
---